COVID-19: IMI2 – Call 21

 

Employee Boehringer IngelheimIn our aspiration to contribute to the fight against COVID-19 with our science, technology and experts, we are actively engaging in ongoing joint projects. We have joined a fast track call initiated by the Innovative Medicines Initiative (IMI) of the European Union by contributing our ongoing COVID-19 projects. IMI has been created by the European Union to accelerate the development of new medical therapies by fostering collaboration between industry and academic research, which makes it an ideal platform to develop treatments against COVID-19.  

Boehringer Ingelheim contributes to the consortium with its leading capabilities and expertise in small molecule and biopharmaceutical drug research, development and manufacturing.  

More related content

COVID-19

COVID-19

As a company, we consider it our duty to take the best possible care of the protection and health of our employees, our patients and society. Boehringer Ingelheim is engaged at various levels of action to contain and cope with the global spread of COVID-19. 

Read more on COVID-19

COVID-19

Protecting Our Employees
Read more on Protecting Our Employees

COVID-19

Animal Health Customers
Read more on Animal Health Customers

COVID-19

Protecting Humans & Animals
Read more on Protecting Humans & Animals

COVID-19

Healthcare Professionals
Read more on Healthcare Professionals